KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(ilings and restatements of previouslyrep...),Health

KV also reported preliminary, unaudited revenue results for its fiscal 2008 third quarter ended December 31, 2007. Net revenues in this period are estimated to be $163.6 million, up 38.7% from fiscal 2007 third quarter net revenues. The Company's Ther-Rx Corporation branded pharmaceutical business contributed approximately $56.3 million, up 16.6% from the prior fiscal year period and comprising 34.4% of KV's total revenue for the period. ETHEX Corporation, KV's generic/non-branded business, contributed approximately $102.1 million of revenue, up 57.7% from the prior-year quarter, primarily due to sales of the 100 mg and 200 mg strengths of metroprolol succinate extended release tablets launched in the second quarter of fiscal 2008. ETHEX Corporation comprises 62.4% of KV's total revenue for the third quarter period. Complete preliminary results for the fiscal third quarter have not yet been reported due to the Company's focus on completing the financial statements for fiscal 2007 as well as the restated results for fiscal 1996 through 2006. KV expects to report its full preliminary third quarter and nine-month fiscal 2008 results in approximately 4 weeks.

Fiscal 2007 Year-End Results

All the financial information presented with this release is unaudited, however, the Company believes that, when filed, its audited financial statements will be consistent with the information presented herein. KV's fiscal 2007 net revenues, for the period ending March 31st, 2007, of $443.6 million represented its 12th consecutive year of record net revenues, led by higher sales from both the Ther-Rx Corporation branded subsidiary, as well as the Company's generic/non-branded subsidiary, ETHEX Corporation. Net earnings were $58.1 million, or $1.05 per diluted Class A Common share compared to $11.4 million, or $0.23 per diluted Class A Common share for fiscal 2006
'/>"/>